3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
30
Rectal Neoplasms
7
Colonic Neoplasms
7
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Stomach Neoplasms
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Solid Tumors
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Locally Advanced Colorectal Carcinoma
1
Liver Neoplasms
1
Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Cancer Metastatic
1
Interventions
Cyclophosphamide
49
fludarabine
36
Dexamethasone
35
venetoclax
29
pembrolizumab
26
Rituximab
21
Lenalidomide
18
pomalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
11
carfilzomib
11
Temozolomide
11
Cisplatin
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Injections
9
Azacitidine
9
selinexor
8
Vincristine
8
Carboplatin
8
Bortezomib
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Bevacizumab
7
zanubrutinib
6
ruxolitinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Folfox protocol
×
1 year
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled